FusionNeoAntigen Logo

Home

Download

Statistics

Examples

Help

Contact

Terms of Use

Center for Computational Systems Medicine
leaf

Fusion Gene and Fusion Protein Summary

leaf

Fusion Amino Acid Sequences (multiple BPs and multiple gene isoforms)

leaf

Fusion Protein Breakpoint Sequences - (for the Screening of the FusionNeoAntigens)

leaf

Potential FusionNeoAntigens in HLA I - (netMHCpan v4.1 + deepHLApan v1.1)

leaf

Potential FusionNeoAntigens in HLA II - (netMHCIIpan v4.1)

leaf

Fusion Breakpoint 14 AA Peptide Structure - (RoseTTAFold)

leaf

Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D - (Glide)

leaf

Vaccine Design for the FusionNeoAntigens (RNA/protein sequences)

leaf

Potential target of CAR-T therapy development

leaf

Information on the samples that have these potential fusion neoantigens

leaf

Fusion Protein Targeting Drugs - (Manual Curation)

leaf

Fusion Protein Related diseases - (Manual Curation)

Fusion Protein:TNXB-VIM

Fusion Gene and Fusion Protein Summary

check button Fusion gene summary
Fusion partner gene informationFusion gene name: TNXB-VIM
FusionPDB ID: 92962
FusionGDB2.0 ID: 92962
HgeneTgene
Gene symbol

TNXB

VIM

Gene ID

7148

7431

Gene nametenascin XBvimentin
SynonymsEDS3|EDSCLL|EDSCLL1|HXBL|TENX|TN-X|TNX|TNXB1|TNXB2|TNXBS|VUR8|XB|XBS-
Cytomap

6p21.33-p21.32

10p13

Type of geneprotein-codingprotein-coding
Descriptiontenascin-Xgrowth-inhibiting protein 45hexabrachion-like proteintenascin XB1tenascin XB2vimentinepididymis secretory sperm binding protein
Modification date2020031320200327
UniProtAcc.

VMAC

Main function of 5'-partner protein: 169
Ensembl transtripts involved in fusion geneENST idsENST00000375244, ENST00000375247, 
ENST00000383159, ENST00000424718, 
ENST00000433037, ENST00000440248, 
ENST00000451343, ENST00000464376, 
ENST00000465958, ENST00000469250, 
ENST00000471059, ENST00000475986, 
ENST00000479795, ENST00000489006, 
ENST00000546684, ENST00000548628, 
ENST00000548649, ENST00000549232, 
ENST00000549652, ENST00000550212, 
ENST00000550539, ENST00000551201, 
ENST00000551808, ENST00000552149, 
ENST00000552665, ENST00000553092, 
ENST00000485947, ENST00000224237, 
ENST00000544301, 
Fusion gene scores for assessment (based on all fusion genes of FusionGDB 2.0)* DoF score4 X 4 X 4=6442 X 25 X 11=11550
# samples 441
** MAII scorelog2(4/64*10)=-0.678071905112638
possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs).
DoF>8 and MAII<0
log2(41/11550*10)=-4.81612513168534
possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs).
DoF>8 and MAII<0
Fusion gene context

PubMed: TNXB [Title/Abstract] AND VIM [Title/Abstract] AND fusion [Title/Abstract]

Fusion neoantigen context

PubMed: TNXB [Title/Abstract] AND VIM [Title/Abstract] AND neoantigen [Title/Abstract]

Most frequent breakpoint (based on all fusion genes of FusionGDB 2.0)TNXB(32016140)-VIM(17278293), # samples:1
Anticipated loss of major functional domain due to fusion event.TNXB-VIM seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF.
TNXB-VIM seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF.
TNXB-VIM seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF.
TNXB-VIM seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF.
* DoF score (Degree of Frequency) = # partners X # break points X # cancer types
** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10)

check button Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez
PartnerGeneGO IDGO termPubMed ID


check button Four levels of functional features of fusion genes
Go to FGviewer search page for the most frequent breakpoint (https://ccsmweb.uth.edu/FGviewer/chr6:32016140/chr10:17278293)
- FGviewer provides the online visualization of the retention search of the protein functional features across DNA, RNA, protein, and pathological levels.
- How to search
1. Put your fusion gene symbol.
2. Press the tab key until there will be shown the breakpoint information filled.
4. Go down and press 'Search' tab twice.
4. Go down to have the hyperlink of the search result.
5. Click the hyperlink.
6. See the FGviewer result for your fusion gene.
FGviewer

check buttonRetention analysis results of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features, are available here.

check buttonFusion gene breakpoints across TNXB (5'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.
all structure

check buttonFusion gene breakpoints across VIM (3'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.
all structure


Top

Fusion Amino Acid Sequences


check buttonFusion information from ORFfinder translation from full-length transcript sequence from FusionPDB.
HenstTenstHgeneHchrHbpHstrandTgeneTchrTbpTstrandSeq length
(transcript)
BP loci
(transcript)
Predicted start
(transcript)
Predicted stop
(transcript)
Seq length
(amino acids)
ENST00000375244TNXBchr632016140-ENST00000544301VIMchr1017278293+1068910247202103743390
ENST00000375244TNXBchr632016140-ENST00000224237VIMchr1017278293+1069710247202103743390
ENST00000375247TNXBchr632016140-ENST00000544301VIMchr1017278293+1068310241202103683388
ENST00000375247TNXBchr632016140-ENST00000224237VIMchr1017278293+1069110241202103683388

check buttonDeepORF prediction of the coding potential based on the fusion transcript sequence of in-frame fusion genes. DeepORF is a coding potential classifier based on convolutional neural network by comparing the real Ribo-seq data. If the no-coding score < 0.5 and coding score > 0.5, then the in-frame fusion transcript is predicted as being likely translated.
HenstTenstHgeneHchrHbpHstrandTgeneTchrTbpTstrandNo-coding scoreCoding score
ENST00000375244ENST00000544301TNXBchr632016140-VIMchr1017278293+0.0008060980.99919397
ENST00000375244ENST00000224237TNXBchr632016140-VIMchr1017278293+0.0008050.99919504
ENST00000375247ENST00000544301TNXBchr632016140-VIMchr1017278293+0.0006477240.9993523
ENST00000375247ENST00000224237TNXBchr632016140-VIMchr1017278293+0.0006467940.99935323

check button Predicted full-length fusion amino acid sequences. For individual full-length fusion transcript sequence from FusionPDB, we ran ORFfinder and chose the longest ORF among all the predicted ones.

Get the fusion protein sequences from here.

Fusion protein sequence information is available in the fasta format.
>FusionGDB ID_FusionGDB isoform ID_FGname_Hgene_Hchr_Hbp_Henst_Tgene_Tchr_Tbp_Tenst_length(fusion AA) seq_BP

Top

Fusion Protein Breakpoint Sequences for TNXB-VIM

check button +/-13 AA sequence from the breakpoints of the fusion protein sequences.
HgeneHchrHbpTgeneTchrTbpLength(fusion protein)BP in fusion proteinPeptide
TNXBchr632016140VIMchr1017278293102413325VAVSGLDPARKYKFLLFGLQNGKRHG
TNXBchr632016140VIMchr1017278293102473327VAVSGLDPARKYKFLLFGLQNGKRHG

Top

Potential FusionNeoAntigen Information of TNXB-VIM in HLA I

check button Multiple sequence alignments of the potential FusionNeoAntigens per fusion breakpoints. If the MSA is empty, then it means that there were predicted fusion neoantigens in this fusion breakpoint, but those predicted fusion neoantigens were not across the breakpoint, which is not fusion-specific.
TNXB-VIM_32016140_17278293.msa

check button Potential FusionNeoAntigen Information
* We used NetMHCpan v4.1 (%rank<0.5) and deepHLApan v1.1 (immunogenic score>0.5)
Fusion geneHchrHbpTgeneTchrTbpHLA IFusionNeoAntigen peptideBinding scoreImmunogenic scoreNeoantigen start (at BP 13)Neoantigen end (at BP 13)
TNXB-VIMchr632016140chr101727829310247HLA-B15:03RKYKFLLF0.94920.6962917
TNXB-VIMchr632016140chr101727829310247HLA-B27:02ARKYKFLLF0.99930.7279817
TNXB-VIMchr632016140chr101727829310247HLA-B27:05ARKYKFLLF0.99920.8687817
TNXB-VIMchr632016140chr101727829310247HLA-B27:04ARKYKFLLF0.99860.7654817
TNXB-VIMchr632016140chr101727829310247HLA-B14:01ARKYKFLLF0.78020.5136817
TNXB-VIMchr632016140chr101727829310247HLA-B14:02ARKYKFLLF0.78020.5136817
TNXB-VIMchr632016140chr101727829310247HLA-B27:14ARKYKFLLF0.99910.8568817
TNXB-VIMchr632016140chr101727829310247HLA-C07:95ARKYKFLLF0.99010.756817
TNXB-VIMchr632016140chr101727829310247HLA-B27:03ARKYKFLLF0.98080.8936817
TNXB-VIMchr632016140chr101727829310247HLA-C07:19ARKYKFLLF0.97310.7855817
TNXB-VIMchr632016140chr101727829310247HLA-C07:27ARKYKFLLF0.97180.9634817
TNXB-VIMchr632016140chr101727829310247HLA-C07:05ARKYKFLLF0.96360.9689817
TNXB-VIMchr632016140chr101727829310247HLA-C07:46ARKYKFLLF0.92510.8635817
TNXB-VIMchr632016140chr101727829310247HLA-C07:67ARKYKFLLF0.92470.9462817
TNXB-VIMchr632016140chr101727829310247HLA-C07:80ARKYKFLLF0.92470.9462817
TNXB-VIMchr632016140chr101727829310247HLA-C07:10ARKYKFLLF0.90560.9537817
TNXB-VIMchr632016140chr101727829310247HLA-B14:03DPARKYKFL0.62360.6385615
TNXB-VIMchr632016140chr101727829310247HLA-C12:16ARKYKFLLF0.0860.9784817
TNXB-VIMchr632016140chr101727829310247HLA-B39:10DPARKYKFL0.08490.72615
TNXB-VIMchr632016140chr101727829310247HLA-B15:68RKYKFLLF0.95430.5897917
TNXB-VIMchr632016140chr101727829310247HLA-B18:07DPARKYKF0.89430.6108614
TNXB-VIMchr632016140chr101727829310247HLA-B27:08ARKYKFLLF0.9990.8007817
TNXB-VIMchr632016140chr101727829310247HLA-B27:10ARKYKFLLF0.99870.8441817
TNXB-VIMchr632016140chr101727829310247HLA-B27:06ARKYKFLLF0.99720.7611817
TNXB-VIMchr632016140chr101727829310247HLA-C07:01ARKYKFLLF0.99490.7518817
TNXB-VIMchr632016140chr101727829310247HLA-B27:09ARKYKFLLF0.98480.8366817
TNXB-VIMchr632016140chr101727829310247HLA-C07:02ARKYKFLLF0.92470.9462817
TNXB-VIMchr632016140chr101727829310247HLA-C07:17ARKYKFLLF0.92310.9699817
TNXB-VIMchr632016140chr101727829310247HLA-C07:22ARKYKFLLF0.78390.7657817
TNXB-VIMchr632016140chr101727829310247HLA-C06:08ARKYKFLLF0.59460.982817
TNXB-VIMchr632016140chr101727829310247HLA-B15:68ARKYKFLLF0.13530.6933817
TNXB-VIMchr632016140chr101727829310247HLA-C06:06ARKYKFLLF0.09750.9898817
TNXB-VIMchr632016140chr101727829310247HLA-C06:17ARKYKFLLF0.05360.9934817
TNXB-VIMchr632016140chr101727829310247HLA-C06:02ARKYKFLLF0.05360.9934817

Top

Potential FusionNeoAntigen Information of TNXB-VIM in HLA II

check button Multiple sequence alignments of the potential FusionNeoAntigens per fusion breakpoints. If the MSA is empty, then it means that there were predicted fusion neoantigens in this fusion breakpoint, but those predicted fusion neoantigens were not across the breakpoint, which is not fusion-specific.

check button Potential FusionNeoAntigen Information
* We used NetMHCIIpan v4.1 (%rank<0.5).
Fusion geneHchrHbpTgeneTchrTbpHLA IIFusionNeoAntigen peptideNeoantigen start (at BP 13)Neoantigen end (at BP 13)

Top

Fusion breakpoint peptide structures of TNXB-VIM

check button3D structures of the fusion breakpoint peptide of 14AA sequence that have potential fusion neoantigens
* The minimum length of the amino acid sequence in RoseTTAFold is 14AA. Here, we predicted the 14AA fusion protein breakpoint sequence not the fusion neoantigen peptide, which is shorter than 14 AA.
File nameBPseqHgeneTgeneHchrHbpTchrTbpAAlen
1292DPARKYKFLLFGLQTNXBVIMchr632016140chr101727829310247

Top

Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D of TNXB-VIM

check buttonVirtual screening between 25 HLAs (from PDB) and FusionNeoAntigens
* We used Glide to predict the interaction between HLAs and neoantigens.
HLA allelePDB IDFile nameBPseqDocking scoreGlide score
HLA-B14:023BVN1292DPARKYKFLLFGLQ-7.29906-7.41686
HLA-B14:023BVN1292DPARKYKFLLFGLQ-3.02415-4.07315
HLA-B52:013W391292DPARKYKFLLFGLQ-5.33357-5.45137
HLA-B52:013W391292DPARKYKFLLFGLQ-3.30193-4.35093
HLA-A24:025HGA1292DPARKYKFLLFGLQ-5.66426-5.78206
HLA-A24:025HGA1292DPARKYKFLLFGLQ-3.36199-4.41099
HLA-B44:053DX81292DPARKYKFLLFGLQ-5.10146-5.21926
HLA-B44:053DX81292DPARKYKFLLFGLQ-4.15316-5.20216
HLA-A02:016TDR1292DPARKYKFLLFGLQ-4.43659-4.55439

Top

Vaccine Design for the FusionNeoAntigens of TNXB-VIM

check button mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-Is.
Fusion geneHchrHbpTchrTbpStart in +/-13AAEnd in +/-13AAFusionNeoAntigen peptide sequenceFusionNeoAntigen RNA sequence
TNXB-VIMchr632016140chr1017278293614DPARKYKFTCCCTGTGGAGGCCAGGACCGAAA
TNXB-VIMchr632016140chr1017278293615DPARKYKFLTCCCTGTGGAGGCCAGGACCGAAACTA
TNXB-VIMchr632016140chr1017278293817ARKYKFLLFTGGAGGCCAGGACCGAAACTAATCTGG
TNXB-VIMchr632016140chr1017278293917RKYKFLLFAGGCCAGGACCGAAACTAATCTGG

check button mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-IIs.
Fusion geneHchrHbpTchrTbpStart in +/-13AAEnd in +/-13AAFusionNeoAntigen peptideFusionNEoAntigen RNA sequence

Top

Information of the samples that have these potential fusion neoantigens of TNXB-VIM

check button These samples were reported as having these fusion breakpoints. For individual breakpoints, we checked the open reading frames considering multiple gene isoforms and chose the in-frame fusion genes only. Then, we made fusion protein sequences and predicted the fusion neoantigens. These fusion-positive samples may have these potential fusion neoantigens.
Cancer typeFusion geneHchrHbpHenstTchrTbpTenstSample
SARCTNXB-VIMchr632016140ENST00000375244chr1017278293ENST00000224237TCGA-DX-AB2T-01A

Top

Potential target of CAR-T therapy development for TNXB-VIM

check button Predicted 3D structure. We used RoseTTAFold.

check buttonRetention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, to provide the retention of the transmembrane domain, we only show the protein feature retention information of those transmembrane features


* Minus value of BPloci means that the break point is located before the CDS.
- In-frame and retained 'Transmembrane'.
PartnerGeneHbpTbpENSTStrandBPexonTotalExonProtein feature loci*BPlociTotalLenProtein featureProtein feature note

check button Subcellular localization prediction of the transmembrane domain retained fusion proteins
* We used DeepLoc 1.0. The order of the X-axis of the barplot is as follows: Entry_ID, Localization, Type, Nucleus, Cytoplasm, Extracellular, Mitochondrion, Cell_membrane, Endoplasmic_reticulum, Plastid, Golgi.apparatus, Lysosome.Vacuole, Peroxisome. Y-axis is the output score of DeepLoc. Clicking the image will open a new tab with a large image.
HgeneHchrHbpHenstTgeneTchrTbpTenstDeepLoc result

Top

Related Drugs to TNXB-VIM

check button Drugs used for this fusion-positive patient.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)
HgeneTgeneDrugSourcePMID

Top

Related Diseases to TNXB-VIM

check button Diseases that have this fusion gene.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)
HgeneTgeneDiseaseSourcePMID

check button Diseases associated with fusion partners.
(DisGeNet 4.0)
PartnerGeneDisease IDDisease name# pubmedsSource